首页> Frontiers in neuroscience> Lectin-type oxidized LDL receptor-1 as a potential therapeutic target for cerebral cavernous malformations treatment.

Lectin-type oxidized LDL receptor-1 as a potential therapeutic target for cerebral cavernous malformations treatment.

导出 OA

翻译打印收藏纠错

第一作者： Karthik,Ashok

第一单位： Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States.;Department of Surgery, Harvard Medical School, Boston, MA, United States.

作者： Karthik,Ashok ^[1] ; Tyra,Martinez ^[1] ; Julie,Sesen ^[1] ; Sana,Nasim ^[2] ; Shih-Shan,Lang ^[3] ; Gregory,Heuer ^[3] ; Alexander,Tucker ^[3] ; Miguel Alejandro,Lopez-Ramirez ^[4] ; Edward R,Smith ^[5] ; Aram,Ghalali ^[1]

作者单位： Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States.;Department of Surgery, Harvard Medical School, Boston, MA, United States. ^[1] Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States. ^[2] Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA, United States.;Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. ^[3] Department of Medicine, University of California, San Diego, CA, United States. ^[4] Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States.;Department of Surgery, Harvard Medical School, Boston, MA, United States.;Department of Neurosurgery, Boston Children's Hospital, Boston, MA, United States. ^[5]

关键词 CCM LOX-1 Olink cerebral cavernous malformations lectin-type oxidized ldl receptor 1 (LOX-1)proximity extension assay (PEA)urinary biomarker

DOI 10.3389/fnins.2024.1442110

PMID 39234183

发布时间 2024-09-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交